Sheridan William P 4

Accession 0001127602-21-018509

CIK 0000882796other

View on SEC.gov Company Profile

Filed

May 31, 8:00 PM ET

Accepted

Jun 1, 4:33 PM ET

Size

28.2 KB

Accession

0001127602-21-018509

Insider Transaction Report

Form 4

Period: 2021-05-27

BIOCRYST PHARMACEUTICALS INCBCRX

Sheridan William P

SR VP - CMO

Transactions

Exercise/Conversion
Common Stock
2021-05-27$5.59/sh+35,701$199,569→ 75,135 total
Sale
Common Stock
2021-05-28$15.02/sh−91,814$1,379,046→ 14,475 total
Exercise/Conversion
Common Stock
2021-05-27$4.73/sh+24,959$118,056→ 39,434 total
Sale
Common Stock
2021-05-27$15.00/sh−71,759$1,076,385→ 14,475 total
Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-28−21,614→ 0 total
Exercise: $4.73From: 2013-03-01Exp: 2022-03-01→ Common Stock (21,614 underlying)
Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-27−35,701→ 64,299 total
Exercise: $5.59From: 2015-03-09Exp: 2022-03-09→ Common Stock (35,701 underlying)
Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-28−5,901→ 0 total
Exercise: $5.45From: 2015-05-13Exp: 2023-08-08→ Common Stock (5,901 underlying)
Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-28−64,299→ 0 total
Exercise: $5.59From: 2015-03-09Exp: 2022-03-09→ Common Stock (64,299 underlying)
Exercise/Conversion
Common Stock
2021-05-28$5.59/sh+64,299$359,431→ 100,388 total
Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-27−11,099→ 5,901 total
Exercise: $5.45From: 2015-05-13Exp: 2023-08-08→ Common Stock (11,099 underlying)
Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-05-27−24,959→ 21,614 total
Exercise: $4.73From: 2013-03-01Exp: 2022-03-01→ Common Stock (24,959 underlying)
Exercise/Conversion
Common Stock
2021-05-27$5.45/sh+11,099$60,490→ 86,234 total
Exercise/Conversion
Common Stock
2021-05-28$4.73/sh+21,614$102,234→ 36,089 total
Exercise/Conversion
Common Stock
2021-05-28$5.45/sh+5,901$32,160→ 106,289 total

Footnotes (3)

[F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 30, 2020.
[F2]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.01. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
[F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

BIOCRYST PHARMACEUTICALS INC

CIK 0000882796

→

Entity typeother

Related Parties

filerCIK 0001439174

Filing Metadata

Form type: 4
Filed: May 31, 8:00 PM ET
Accepted: Jun 1, 4:33 PM ET
Size: 28.2 KB

View on SEC.gov